Nanomedicine : nanotechnology, biology, and medicine最新文献

{"title":"4HPR nanoformulation regulates MAPKAPK3/3pK signaling to control Bax phosphorylation and mitochondrial translocation to execute apoptosis in neuroblastoma","authors":"Angela Sharma,&nbsp;Atul Dev,&nbsp;Subhasree Roy Choudhury,&nbsp;Surajit Karmakar","doi":"10.1016/j.nano.2025.102858","DOIUrl":"10.1016/j.nano.2025.102858","url":null,"abstract":"<div><div>Neuroblastoma (NB) is a neuroendocrine tumor derived from neural crest progenitor cells, commonly arising along the sympathetic nervous system, especially in the adrenal medulla. Despite therapeutic advances, the prognosis for advanced-stage NB remains poor, necessitating improved treatment options. 4HPR has demonstrated cytotoxicity in various tumors, including NB, with low systemic toxicity; however, its clinical use is restricted by poor solubility and bioavailability. To address this, we developed a human serum albumin-based nanoformulation of 4HPR using a simple desolvation method. This formulation effectively induced apoptosis in NB cells, marked by increased ROS generation, elevated Bax/Bcl-2 ratio, and enhanced cell detachment. Notably, we identified for the first time that MAPKAPK3 downregulation leads to reduced Bax phosphorylation and increased mitochondrial translocation. Co-immunoprecipitation confirmed a direct MAPKAPK3–Bax interaction, indicating MAPKAPK3 regulates Bax via phosphorylation. Our nanoformulation modulates this cross-talk, demonstrating promising translational potential as a novel therapeutic strategy for neuroblastoma.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"70 ","pages":"Article 102858"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zebrafish as a model for assessing the nanotechnology-based approaches in cancer diagnosis, therapy and theranostic: A historical review, trends and challenges","authors":"Jaqueline Cardoso Jacintho ,&nbsp;Ana Clara Nogueira Ferreira ,&nbsp;Thiago Lopes Rocha","doi":"10.1016/j.nano.2025.102867","DOIUrl":"10.1016/j.nano.2025.102867","url":null,"abstract":"<div><div>Nanotechnology-based approaches (NBA) can improve tumor diagnosis and treatment. Thus, zebrafish (<em>Danio rerio</em>) emerge as a model system to investigate antitumoral effects, biodistribution and mechanism of action of nanomaterials (NMs). The current study aimed to summarize and critically analyze the literature concerning the use of zebrafish as an <em>in vivo</em> model for assessing the NBA in diagnosis, therapy and theranostics of cancer. Revised data (n = 95) showed an increasing number of publications in recent years. The main study approach was therapeutic (83.16 %), while diagnosis and theranostics represented 9.47 % and 7.37 %, respectively. 95.8 % used the embryo-larval stage of zebrafish. The most studied NM was the nanoparticles (NPs). Breast cancer, liver and melanoma were the tumors most studied. Overall, NMs can reduce chemotherapeutic drug toxicity, inhibit tumor growth, metastasis and angiogenesis, also promote tumor imaging and tracking. Zebrafish is a suitable emerging model system in cancer nanomedicine research.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"70 ","pages":"Article 102867"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145275425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-targeting exosome vaccine confers efficient protection against CVB3-induced myocarditis","authors":"Qinghui Cao ,&nbsp;Yihui Ge ,&nbsp;Tong Wang,&nbsp;Ke Lin,&nbsp;Sidong Xiong,&nbsp;Yan Yue","doi":"10.1016/j.nano.2025.102865","DOIUrl":"10.1016/j.nano.2025.102865","url":null,"abstract":"<div><div>Coxsackievirus B3 (CVB3) is a common cause of viral myocarditis, necessitating the development of prophylactic vaccines.. AD-Exo, a dual-targeting exosome vaccine, was developed to induce immune responses via targeting draining lymph nodes (dLNs) and dendritic cells (DCs). By incorporating an albumin-binding domain (ABD) peptide and a DC-guiding peptide (DCpep) into our previous CVB3 exosome vaccine (Exo), the AD-Exo vaccine demonstrated superior immunogenicity. It efficiently bound to mouse serum albumin, amplified antigen enrichment in dLNs, and enhanced DC uptake and maturation. Subcutaneous immunization in mice elicited significantly higher CVB3-specific serum neutralizing IgG with greater affinity than Exo and single-targeting vaccines. It induced robust T cell proliferation and CTL responses, increasing IFN-γ-producing CD4⁺ and CD8⁺ T cells. Ultimately, the AD-Exo vaccine reduced cardiac viral load, minimized histopathological damage, and significantly improved survival in challenged mice. This strategy provided novel perspectives for the development of dual-targeting prophylactic vaccines against viral myocarditis.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"70 ","pages":"Article 102865"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Schisandrin-loaded β-cyclodextrin nanoparticles for atherosclerosis therapy","authors":"Qiuxia Huang,&nbsp;Xinyao Liu,&nbsp;Jinjin Yu,&nbsp;Xinya Zhang,&nbsp;Siqi Wang,&nbsp;Lili Zhou,&nbsp;Xiaofeng Niu,&nbsp;Weifeng Li","doi":"10.1016/j.nano.2025.102866","DOIUrl":"10.1016/j.nano.2025.102866","url":null,"abstract":"<div><div>Nanoparticle delivery systems have been extensively investigated as novel therapeutic strategies to promote drug-resistant disease. These nanoparticle formulations demonstrated improved bioavailability and enhanced tissue targeting. Also, there is growing acceptance of the value of traditional Chinese medicine in fighting disease. In this study, combining the advantages of nanomedicine with the characteristics of the acidic inflammatory microenvironment of atherosclerosis, a nanoplasmonic platform encapsulating the unstable drug Sch was designed for the treatment of atherosclerotic lesions. pH-responsive nanocarriers, an acid-labile material of acetylated β-cyclodextrin (β-CD) (Ac-bCD) were synthesized by chemical modification of β-CD. The resulting nanoparticles loaded with Sch (Sch-NPs) were prepared using a solvent evaporation method. In ApoE^−/− mice fed a high-fat diet, Sch-NPs alleviated arterial damage, inhibited lipid metabolism disorders, reduced plaque area, and promoted plaque stability. In addition, Sch-NPs effectively reduced inflammatory infiltration and oxidative stress by modulating the MAPK pathway. Our findings demonstrate the promising applications of pH-responsive nanoparticles loaded with Sch for enhanced disease therapies such as atherosclerosis.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"70 ","pages":"Article 102866"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145280912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3D correlative light and electron microscopy reveals the uptake and processing of inorganic-organic hybrid nanoparticles into cancer cells","authors":"Louisa Herbsleb ,&nbsp;David Wild ,&nbsp;Henriette Gröger ,&nbsp;Tim Schubert ,&nbsp;Anna Maria Steyer ,&nbsp;Julian Hennies ,&nbsp;Frauke Alves ,&nbsp;Claus Feldmann ,&nbsp;Andreas Walter","doi":"10.1016/j.nano.2025.102872","DOIUrl":"10.1016/j.nano.2025.102872","url":null,"abstract":"<div><div>Inorganic–organic hybrid nanoparticles (IOH-NPs) are a promising drug delivery system in oncology due to their high drug-load capacity. In this study, we established a 3D correlative light and electron microscopy (CLEM) workflow that combines confocal fluorescence microscopy (FM) with focused ion beam scanning electron microscopy (FIBSEM) to unambiguously identify and visualize the (sub)cellular uptake and processing of reference fluorescently labeled and zirconium-based IOH-NPs in murine H8N8 breast cancer cells. The 3D-CLEM workflow was set up without the need to add external fiducial markers since image correlation was achieved using lipid droplets as intrinsic correlative landmarks. We observed that all H8N8 breast cancer cells had taken up IOH-NPs after 4 h, and most IOH-NPs were found in clusters within the H8N8 cells. IOH-NPs were internalized by endocytosis within 2 h with increasing cellular concentrations over time and accumulated in endolysosomal vesicles over 24 h, while the overall endolysosomal volume increased between 2 and 6 h after IOH-NP incubation and returned to its original value thereafter, remaining stable for up to 48 h. The 3D-CLEM workflow also revealed changes in the morphology and density of the IOH-NPs inside endolysosomal vesicles, suggesting the dissolution of IOH-NPs after 2 h. We also observed mitochondrial swelling in IOH-NP exposed cells, suggesting stress responses even without drug load. The 3D-CLEM workflow provides new insights into the cellular tracking and processing of IOH-NPs and supports the development of novel nanomedicine strategies.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"70 ","pages":"Article 102872"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145368470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of growth of the human chronic leukemia cancer cell line K562 using capsaicin-containing nanofibers: an in vitro study","authors":"Mohadeseh Heidarzadeh ,&nbsp;Habib Hamidinezhad ,&nbsp;Fatemeh Hedayati Tabari ,&nbsp;Mohammad Karimian","doi":"10.1016/j.nano.2025.102864","DOIUrl":"10.1016/j.nano.2025.102864","url":null,"abstract":"<div><div>This study aims to investigate the anticancer properties of capsaicin, the active substance of red pepper, in different concentrations (2 %, 6 %, and 10 %) by chitosan and polyvinyl alcohol nanofiber substrate, against the K562 leukemia cell line. For this purpose, chitosan (Cs) and polyvinyl alcohol (PVA) polymers were used to produce nanofibers with a 20/80 ratio by electrospinning, with capsaicin serving as the anticancer drug. The properties of the fabricated nanofibers were evaluated by field emission scanning electron microscopy. Also, gold nanoparticles were used to analyze and compare its effectiveness against the K562 cancer cell line. This cell line was prepared from Pasteur cell bank and cultured in DMEM medium. Subsequently, the anticancer effect of synthetic nanofibers in different concentrations was assessed by performing survival test, apoptosis by annexin and propidium iodide staining, and cell scratch assay. The electron microscopy study demonstrated the uniformity and purity of the nanofiber structure. The results showed that capsaicin, dose-dependently, reduced the viability of K562 cells after 72 h (<em>P</em> &lt; 0.01). The apoptotic assay also indicated that the induction of apoptosis significantly increased by PVA/Cs/Caps(2 %) and PVA/Cs/Au(5 %)/Caps(10 %) compounds in the studied cell line (<em>P</em> &lt; 0.0001). Furthermore, scratch assay at 24, 48, and 72 h demonstrated that the mentioned compounds possess anti-migration potential, particularly at 48 h. Our results suggest that capsaicin in nanofiber substrate can show anticancer properties against the K562 leukemia cell line. Therefore, this compound can be considered a potential candidate for the treatment of leukemia.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"70 ","pages":"Article 102864"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic potential and toxicological challenges of metal nanoparticles in drug delivery: A comprehensive review","authors":"Sajid Mehmood ,&nbsp;Sajiya Iraqui ,&nbsp;Rajesh Kumar Ojha ,&nbsp;Nisha Sharma ,&nbsp;Ab Rahman Marlinda","doi":"10.1016/j.nano.2025.102862","DOIUrl":"10.1016/j.nano.2025.102862","url":null,"abstract":"<div><div>Metal nanoparticles (NPs) have emerged as advanced drug delivery systems, combining high therapeutic potential with complex safety considerations. Their unique physicochemical features, including high surface-to-volume ratios, tunable surfaces, and the ability to cross biological barriers, enable applications in targeted drug delivery and theranostics. Gold (Au), silver (Ag), iron oxide (Fe₃O₄), zinc oxide (ZnO), and platinum (Pt) NPs demonstrate outstanding efficacy: AuNPs achieve &gt;90 % drug loading and 3–5× improved tumour targeting, AgNPs show up to 99 % antimicrobial activity, and Fe₃O₄ NPs function as both drug carriers and MRI contrast agents. However, toxicity remains a major hurdle. Reported challenges include dose-dependent cytotoxicity (IC₅₀: 10–40 μg/mL), hepatic retention (30–40 %), oxidative stress (2–10× ROS increase), and immune activation (up to 3-fold cytokine elevation). Safety is governed by physicochemical properties, with &lt;10 nm NPs showing efficient penetration but higher genotoxicity, and cationic surfaces being 2–3× more cytotoxic. Several strategies have been developed to overcome these barriers. PEGylation reduces macrophage uptake by 60–75 % and extends circulation time, biodegradable hybrids reduce long-term accumulation by 70–80 %, and controlled-release systems cut doses by 30–50 % without compromising efficacy. Advances in computational tools, such as machine learning (~87 % predictive accuracy), along with standardized testing (&lt;20 % variability), have accelerated preclinical evaluation by 40–50 %. These improvements contribute to therapeutic indices &gt;10 and Phase I trial success rates of 65–75 %, significantly outperforming first-generation nanocarriers. This review highlights the need for multidisciplinary integration of nanotechnology, toxicology, computational modelling, and regulatory frameworks. With continued innovation, metal NPs hold the potential to revolutionize precision medicine through safer, scalable, and clinically translatable nanoplatforms.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"70 ","pages":"Article 102862"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A state-of-the-art review on inhalable nanoconjugates for targeted drug delivery in acute lung injury: Advances, challenges and future directions","authors":"Piyushkumar Sadhu ,&nbsp;Mamta Kumari ,&nbsp;Nirmal Shah ,&nbsp;Niyati Shah ,&nbsp;Chitrali Talele ,&nbsp;Falguni Rathod","doi":"10.1016/j.nano.2025.102873","DOIUrl":"10.1016/j.nano.2025.102873","url":null,"abstract":"","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"70 ","pages":"Article 102873"},"PeriodicalIF":4.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145466929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highly fluorescent sustainable SnWO4 nanoparticles as contrast agent for computed tomography (CT)","authors":"Sk Najrul Islam ,&nbsp;Mudasir Ashraf Shah ,&nbsp;Mukesh Kumar ,&nbsp;Amit Jaiswal ,&nbsp;Gulbuddin Hekmotiar ,&nbsp;Manish Dixit ,&nbsp;Sanjay Gambhir ,&nbsp;Ajay Kumar ,&nbsp;Absar Ahmad","doi":"10.1016/j.nano.2025.102859","DOIUrl":"10.1016/j.nano.2025.102859","url":null,"abstract":"<div><div>X-ray computed tomography (CT) is extensively used in medicine and research, often requiring iodine-based contrast agents which can cause adverse effects in iodine-intolerant patients. Considering safer alternatives, we have biosynthesized and comprehensively characterized highly fluorescent tin tungstate nanoparticles (SnWO₄ NPs) with a size of 40 nm, and compared their effectiveness as contrast agents in CT imaging with that of the commercially available OMNIPAQUE^TM Iohexol injection. The comparative analysis at 80 kVp showed that the highest CT numbers at 10 mg/ml were 2106 ± 101 for iodine and 1477 ± 40 for SnWO₄ NPs, while the lowest at 1 mg/ml were 63 ± 10 and 45 ± 13, respectively. The in vitro cytotoxicity of SnWO₄ NPs against HEK-293 cells, splenocytes, and thymocytes together with their biodistribution in healthy Wistar rats was evaluated revealing minimal toxicity. These findings indicate that SnWO₄ NPs hold significant promise for biomedical imaging applications, demonstrating excellent contrast performance and positioning them as strong candidates for future use as contrast agents.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"69 ","pages":"Article 102859"},"PeriodicalIF":4.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liposomal drug delivery system for lung diseases: Recent advancement and future perspectives","authors":"Saroj Bashyal ,&nbsp;Newton Suwal ,&nbsp;Rajan Thapa ,&nbsp;Laxmi Regmi Bagale ,&nbsp;Vrashabh V Sugandhi ,&nbsp;Sapana Subedi ,&nbsp;Sobia Idrees ,&nbsp;Nisha Panth ,&nbsp;Bassma H. Elwakil ,&nbsp;Mostafa El-Khatib ,&nbsp;Kamal Dua ,&nbsp;Keshav Raj Paudel PhD","doi":"10.1016/j.nano.2025.102855","DOIUrl":"10.1016/j.nano.2025.102855","url":null,"abstract":"<div><div>Lung diseases such as asthma, chronic respiratory diseases, and lung cancer are among the most prevalent and vulnerable health conditions. Various therapeutic approaches, including nucleic acids, peptides, and small molecules have been developed along with different delivery strategies for their treatment. Liposomes have been recognized as promising delivery candidates attributed to their biocompatibility, biodegradability, and ability to encapsulate both hydrophilic and hydrophobic drugs effectively. Their composition closely resembles pulmonary surfactants and can facilitate targeting deep lung tissue while also allowing localized drug delivery with less systemic exposure. The most rigorously explored route for delivering liposomal formulations to the lungs is inhalation. Additionally, liposomes help combat antimicrobial resistance and enhance targeted drug delivery by utilizing stimuli-responsive liposomes or modifying their physicochemical properties. Herein, we explore the liposomal delivery of different classes of drugs, their therapeutic potential in the treatment of lung disease, and discuss perspectives on clinical translation.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"69 ","pages":"Article 102855"},"PeriodicalIF":4.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}